The GLP is committed to full transparency. Download and review our Annual Report.

CAR-T cell therapy could drive a ‘revolution’ in cancer treatments

| | February 28, 2018

[T]he United States Food and Drug Administration (FDA) made the landmark decision to approve two ‘drugs’ that use CAR-T cell therapy – the injection of engineered immune cells into patients – to treat blood cancers. First, in August 2017 it approved Kymriah, a treatment developed by drug company Novartis for acute lymphoblastic leukemia (ALL) in children and young adults. Then in October 2017 it licensed Yescarta, a Gilead Sciences drug for adult diffuse large B-cell lymphoma.

The FDA’s decision heralds a new era of personalised cancer treatment. By using the patient’s own cells, CAR-T cell therapy makes it unlikely that tissue will be rejected. Additionally, the one-off infusion gets around the problem of multiple treatment rounds that characterise other cancer drugs, like chemotherapy. There are fewer side effects, and researchers have also proved its longevity: results from a clinical trial of Kymriah released in February show that 76 per cent of the cancer patients survived for a year or more, something unheard of with other treatments.

[Immunotherapist Bruce] Levine predicts that the next FDA approvals will be for myeloma, a bone marrow cancer for which therapy development is currently underway. Next up will be tumour-based cancers.

[T]o reach more people, it undoubtedly needs to get cheaper. Levine thinks that as more gene therapies are developed, it should drive a revolution in the way we manufacture these drugs.

Read full, original post: Gene-modification is the next frontier in the fight against cancer

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend